Qfitlia (fitusiran) is the first therapy for both hemophilia A or B, with or without inhibitors, available in the United States.

The FDA has recently approved two new prophylactic treatments for people with hemophilia who develop antibodies to clotting ...

Fitusiran is a small interference RNA therapeutic designed to prevent bleeds in patients with hemophilia A or B by lowering antithrombin.

This week, the FDA approved Sanofi’s SNY hemophilia therapy, fitusiran, Novartis’ NVS Vanrafia for the reduction of ...

The U.S. Food and Drug Administration has approved Sanofi's Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce ...

The FDA has approved fitusiran, now Qfitlia, as a treatment for hemophilia A or B patients, ages 12 and older, with or ...

The U.S. Food and Drug Administration on Friday approved Sanofi SA’s (NASDAQ:SNY) Qfitlia (fitusiran), the first antithrombin ...

Unlike other hemophilia therapies, Qfitlia is indicated for both hemophilia A and B, and can be given in patients regardless ...

Qfitlia approved as the first therapy in the US to treat hemophilia A or B with or without inhibitors Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent ...

Qfitlia (fitusiran), the first antithrombin-lowering therapy in hemophilia, offers consistent protection with as few as six injections a year via a prefilled pen or vial and syringe Unique mechanism ...

approval of Qfitliatm (fitusiran), the sixth Alnylam-discovered RNAi therapeutic approved in the U.S., and the first and only therapeutic to lower antithrombin (AT), a protein that inhibits blood ...